

EDITORIAL ADVISORY PANEL

- K. Adler (Raleigh, NC)
C. Austin (Manchester)
R. C. Benyon (Southampton)
D. Bhatnagar (Oldham)
I. Biaggioni (Nashville, TN)
C. E. Brightling (Leicester)
A. Burt (Newcastle upon Tyne)
H. Cai (Chicago, IL)
D. Callen (Adelaide, S. Aus.)
J. D. Cameron (Dandenong, Vic.)
A. Carter (Leeds)
J. P. F. Chin-Dusting (Melbourne)
P. Chowienczyk (London)
S. Duthie (Aberdeen)
K. Evans (Stafford)
E. L. Fallen (Hamilton, Ont.)
A. Ferrante (North Adelaide)
J. Firth (Cambridge)
J. Floras (Toronto)
G. A. Ford (Newcastle upon Tyne)
J. Franklyn (Birmingham)
D. Freeman (Glasgow)
G. J. Gibson (Newcastle upon Tyne)
S. Gough (Birmingham)
A. Graham (Glasgow)
G. Grassi (Milan)
D. J. Green (Nedlands, WA)
F. R. Green (Oxford)
P. Greenhaff (Nottingham)
M. Grimm (Kogarah, NSW)
N. Haites (Aberdeen)
M. Hayashi (Saitama, Japan)
M. Hecker (Goettingen)
J. D. Imig (Augusta, GA)
E. W. Inscho (Augusta, GA)
B. Jilma (Vienna)
R. Johnson (New Orleans)
L. Kritharides (Sydney)
D. S. Kumararatne (Cambridge)
- K.-H. Le Quan Sang (Paris)
M. E. J. Lean (Glasgow)
M. M. Levi (Amsterdam)
P. Little (Melbourne)
D. Lobo (Nottingham)
R. A. Malik (Manchester)
D. A. Mann (Southampton)
J. Mullins (Edinburgh)
S. Nagueh (Houston, TX)
L. Ng (Leicester)
M. J. O'Leary (Sydney)
T. Omland (Oslo)
G. Parati (Milan)
G. Piccirillo (Rome)
C. D. Pusey (London)
M. Rademaker (Christchurch, NZ)
J. Rhodes (Liverpool)
R. Rush (Adelaide)
J. E. Sanderson (Hong Kong)
F. C. Schmalstieg, Jr (Galveston)
T. Shimosawa (Tokyo)
C. C. Shoulders (London)
J. Staessen (Leuven)
H. Stauss (Berlin)
I. Striz (Prague)
S. R. Thomas (Sydney)
N. C. Thomson (Glasgow)
H. Tomiyama (Tokyo)
J. H. M. Tulen (Rotterdam)
J. J. Van Lieshout (Amsterdam)
M. Verma (Bethesda)
J. Wernerman (Huddinge)
M. J. West (Chermside, QLD)
M. J. White (Birmingham)
J. Wilson (Bankstown, NSW)
R. Woodman (Perth, WA)
C. Zhang (Memphis)
J. Zicha (Prague)

**Published by Portland Press on behalf of the
Biochemical Society**

© **The Biochemical Society 2005**

ISSN 0143-5221

Printed in Great Britain by the Charlesworth Group, Wakefield

A U T H O R I N D E X

- A**bián, J. 167–178
 Akatsu, T. 339–347
 Almdal, T. 323–329
 Alonso-Orgaz, S. 85–91
 Andersson, J. 179–184
 Androne, A. S. 331–338
 Astrup, A. 323–329
- B**abich, J. P. 37–46
 Baek, K.-H. 237–243
 Bai, T. R. 463–477
 Baker, A. M. 497–506
 Baker, P. 457–462
 Banya, W. 433–439
 Bargagli, E. 273–276
 Belza, A. 323–329
 Bergström, G. 531–538
 Best, J. D. 497–506
 Bezerra, D. G. 349–355
 Bigliuzzi, C. 273–276
 Bithell, A. 13–22
 Björkhem, I. 507–513
 Bleeker, M. W. P. 151–157
 Böhm, F. 357–363
 Bratholm, P. 323–329
 Brennan, L. 185–194
 Bulpitt, C. J. 433–439
 Burke, A. S. 265–272
 Burke, Z. D. 309–321
 Busca, G. 523–530
- C**ameron, J. 433–439
 Can, G. 129–135
 Cao, Y.-B. 547–552
 Carrascal, M. 167–178
 Carrasco, C. 85–91
 Castoldi, G. 523–530
 Chandra, A. 265–272
 Charbeneau, R. P. 479–491
 Chen, D. 81–84
 Chia, S. 65–72
 Christensen, M. 113–119
 Christensen, N. J. 323–329
 Christov, S. 497–506
 Corder, R. 255–263
 Cowan, P. J. 47–53
- Cox, R. A. 265–272
 Curi, R. 245–253
 Cury-Boaventura, M. F. 245–253
- d'**Apice, A. J. F. 47–53
 Davidson, B. R. 55–63
 Davies, K. E. 385–397
 Dawson, E. 73–80
 de Graaf, J. 425–431
 del Mar González, M. 85–91
 de Meer, K. 449–456
 Diczfalusy, U. 507–513
 di Gioia, C. R. T. 523–530
 Dimayuga, C. 331–338
 Dong, M. 81–84
 Douthwaite, J. A. 255–263
 Dwyer, K. 497–506
- E**dwards, B. 73–80
 Elghozi, J.-L. 225–230
 Enis, S. 37–46
 Enkhabaatar, P. 265–272
 Escribano-Burgos, M. 85–91
 Evans, T. W. 413–424
 Eveson, D. J. 441–447
- F**ang, Q. 81–84
 Fields, M. 37–46
 Fitzpatrick, J. M. 1–11
 Flapan, A. D. 65–72
 Forster, J. 73–80
 Freyschuss, A. 507–513
- G**aitini, L. 37–46
 Gan, L.-m. 531–538
 García-Arumí, E. 167–178
 García-Méndez, A. 85–91
 Gaze, D. 73–80
 Ge, D. 137–142
 George, K. 73–80
 Gillham, J. 457–462
 Gioeli, D. 293–308
 Girard, A. 225–230
 Gladdish, S. 433–439
- Glantzounis, G. 55–63, 159–165
 Gonon, A. T. 357–363
 Gonzalo, R. 167–178
 Gorrell, M. D. 277–292
 Gu, D. 137–142
- H**ägg, U. 531–538
 Hahn, R. G. 217–224
 Hamilton, G. 159–165
 Harvey, J. N. 231–236
 Hawkins, H. K. 265–272
 Hayashi, K. 143–150
 He, J. 81–84
 Hedin, A. 217–224
 Henriksson, P. 507–513
 Hergenç, G. 129–135
 Herndon, D. N. 265–272
 Higashida, H. 143–150
 Hiramori, K. 339–347
 Hofman, M. K. 539–545
 Holewijn, S. 425–431
 Hopman, M. T. E. 151–157
 Hoshi, N. 143–150
 Hryniewicz, K. 331–338
 Huang, J. 137–142
 Hudaihed, A. 331–338
- I**bsen, H. 113–119
 Ino, H. 143–150
 Irvine, R. 457–462
 Isseroff, H. 37–46
- J**akobs, C. 449–456
 Jankowski, K. 331–338
 Januszkievicz, A. 179–184
 Jenkins, A. J. 497–506
 Jeon, W.-K. 553–559
 Johansson, M. E. 531–538
 Jukema, J. W. 539–545
- K**aestner, K. H. 195–204
 Kalogerakis, G. 497–506
 Kamesh, L. 101–112
 Kaneda, T. 143–150
 Kang, J.-H. 237–243
- Kang, M.-I. 237–243
 Katahira, J. 265–272
 Katz, S. D. 331–338
 Kibayashi, E. 515–521
 Kim, B.-I. 553–559
 Kim, B.-J. 237–243
 Kim, B.-S. 237–243
 Kim, S.-W. 237–243, 553–559
 Kim, S.-Y. 237–243
 Kishida, M. 515–521
 Klaude, M. 179–184
 Knight, D. A. 463–477
 Knight, K. R. 47–53
 Kobashi, C. 515–521
 Kobayashi, M. 515–521
 Kofler, S. 205–213
 Kolch, W. 369–383
 Koti, R. S. 55–63
- L**antz, K. A. 195–204
 Laude, D. 225–230
 Lee, M.-H. 237–243
 Lee, W.-Y. 237–243, 553–559
 Lees, D. M. 255–263
 Leitch, H. 231–236
 Leonini, A. 273–276
 Li, H.-L. 547–552
 Liu, D. 137–142
 Long, R. M. 1–11
 López-Farré, A. 85–91
 López-Hellín, J. 167–178
 Loré, K. 179–184
 Lu, Q. 507–513
 Ludlam, C. A. 65–72
- M**abuchi, H. 143–150
 Macaya, C. 85–91
 Macleod, M. 457–462
 Maechler, P. 185–194
 Manawadu, D. 433–439
 Mandarim-de-Lacerda, C. A. 349–355
 Manzella, D. 93–99
 Mateos-Cáceres, P. J. 85–91

- Mead, P. A. 231–236
 Melley, D. D. 413–424
 Mires, G. 457–462
 Mischak, H. 369–383
 Morrison, W. A. 47–53
 Morrissey, C. 1–11
 Myers, J. 457–462
 Myint, F. 159–165
- N**
 Nakamura, M. 339–347
 Naschitz, J. E. 37–46
 Naschitz, S. 37–46
 Newby, D. E. 65–72
 Newsholme, P. 185–194
 Nickel, T. 205–213
 Nightingale, S. 365–367
 Nikiforakis, N. 273–276
 Nygren, A. 121–128
 Nyström, T. 121–128
- O**
 Oh, E.-S. 237–243
 Oh, K.-W. 237–243
 Oliver, P. L. 385–397
 Onat, A. 129–135
 Oshima, T. 143–150
 Oxborough, D. 73–80
- P**
 Panerai, R. B. 441–447
 Paolisso, G. 93–99
 Park, H.-S. 237–243
 Park, J.-R. 237–243
 Park, S.-H. 553–559
 Paul, S. K. 441–447
 Pearson, M. 365–367
 Peck, S. 37–46
 Perari, M. G. 273–276
 Pernow, J. 357–363
 Peters-Golden, M. 479–491
 Pitt, A. R. 369–383
- Porres Cubero, J. C. 85–91
 Potter, J. F. 441–447
 Princen, H. M. G. 539–545
- Q**
 Quaglia, A. 55–63
 Quinlan, G. J. 413–424
- R**
 Rademaker, M. T. 23–36
 Rajkumar, C. 433–439
 Rasmussen, M. 323–329
 Redaelli, S. 523–530
 Rhee, E.-J. 237–243, 553–559
 Richards, A. M. 23–36
 Rico, L. A. 85–91
 Ringdén, O. 179–184
 Robinson, T. G. 441–447
 Romeo-Meeuw, R. 47–53
 Rooyackers, O. 179–184
 Rosner, I. 37–46
 Rottoli, P. 273–276
 Rowley, K. G. 497–506
 Rozenbaum, M. 37–46
 Rubi, B. 185–194
 Rubin Peck, E. 37–46
 Rutherford, P. A. 231–236
 Ryu, S.-H. 553–559
- S**
 Sabo, E. 37–46
 Salman, M. 159–165
 Sansoy, V. 129–135
 Sari, I. 129–135
 Sato, A. 515–521
 Satoh, M. 339–347
 Savage, C. O. S. 101–112
 Seifalian, A. M. 55–63, 159–165
 Sethi, A. S. 255–263
 Settergren, M. 357–363
- Shah, N. S. 441–447
 Shave, R. 73–80
 Shen, F.-M. 547–552
 Shimizu, M. 143–150
 Shimoda, K. 265–272
 Shimoda, Y. 339–347
 Shinkel, T. A. 47–53
 Simson, R. 73–80
 Sjöholm, Å. 121–128
 Smits, P. 151–157
 Smulders, Y. M. 449–456
 Sperti, G. 523–530
 Stalenhoef, A. F. H. 425–431
 Stam, F. 449–456
 Stehouwer, C. D. A. 449–456
 Stella, A. 523–530
 Stephenson, C. 73–80
 Su, D.-F. 547–552
 Su, S. 137–142
 Sumita, R. 143–150
 Sung, K.-C. 237–243
 Szmítko P. E. 493–495
- T**
 Taggart, M. 457–462
 Takata, M. 515–521
 Tejada, M. 167–178
 Terai, H. 143–150
 ter Avest, E. 425–431
 Thijssen, D. H. J. 151–157
 Thomas, T. H. 231–236
 Tosh, D. 309–321
 Toubro, S. 323–329
 Traber, D. L. 265–272
 Traber, L. D. 265–272
 Trang, H. 225–230
- U**
 Urakaze, M. 515–521
 Uyarel, H. 129–135
 Uzunlar, B. 129–135
- V**
 van de Borne, P. 215–216
 van de Greef, W. M. M. 523–530
 van Guldener, C. 449–456
 Verma S. 493–495
 Vilà, M. R. 167–178
- W**
 Wang, X. 81–84
 Watson, R. W. G. 1–11
 Watts, S. W. 399–412
 Webb, D. J. 65–72
 Weis, M. 205–213
 Wernerman, J. 179–184
 Whyte, G. 73–80
 Wickman, A. 531–538
 Wikström, J. 531–538
 Williams, B. P. 13–22
 Williams, J. M. 101–112
 Wilmshurst, P. 365–367
 Wilson, R. 65–72
 Winterbourn, C. 497–506
 Woo, H.-Y. 237–243
 Worck, R. 113–119
 Wretling, B. 507–513
- X**
 Xie, H.-H. 547–552
- Y**
 Yamaguchi, M. 143–150
 Yamazaki, K. 515–521
 Yang, Wenjie 137–142
 Yang, Wenxuan 55–63, 159–165
 Yang, Z. 81–84
 Yao, C. 137–142
 Yazici, M. 129–135
- Z**
 Zheng, H. 331–338
 Zwinderman, A. H. 539–545

S U B J E C T I N D E X

- α -**A**lducin polymorphism
essential hypertension,
sodium–lithium countertransport
231–236
- Adenosine deaminase
dipeptidyl peptidase IV (DPIV),
post-proline aminopeptidase
277–292
- Adipose tissue
catecholamine, weight loss 323–329
- Airway obstruction
endothelin receptor antagonist,
smoke inhalation and burn injury
265–272
- Airway remodelling
asthma, smooth muscle 463–477
- Amino acid metabolism
 β -cell, diabetes 185–194
- Androgen receptor
prostate cancer, Ras signalling
293–308
- Angiotensin
frizzled, vascular smooth muscle
523–530
- Angiotensin-converting enzyme (ACE)
endothelial function, heart failure
331–338
- Antineutrophil cytoplasm antibody
(ANCA)
neutrophil, small vessel vasculitis
101–112
- Aortic stiffness
baroreceptor sensitivity, ischaemic
stroke 441–447
- Apoptosis
neutrophil, systemic inflammatory
response syndrome (SIRS)
413–424
- Ascorbic acid (vitamin C)
diabetes, oxidative stress 507–513
- Asthma
airway remodelling, smooth muscle
463–477
- Atherosclerosis
cholesterol metabolism,
polymorphism 539–546
- C-reactive protein (CRP),
osteoprotegerin 237–243
- Autologous plasma
protein clearance, volume
expansion 217–224
- Autonomic nervous system
cardiac autonomic neuropathy,
Type II diabetes 93–99
- B**aroreceptor sensitivity
aortic stiffness, ischaemic stroke
441–447
hypertension, organ damage
547–552
- Blood flow
vascular resistance, venous
occlusion plethysmography
151–157
- Blood pressure
congenital central hypoventilation
syndrome, heart rate variability
215–216, 225–230
5-hydroxytryptamine (5-HT),
hypertension 399–412
- Blood pressure variability
hypertension, ketanserin 547–552
- Bosentan
endothelial dysfunction,
ischaemia/reperfusion 357–363
- Bronchoalveolar lavage
chronic eosinophilic pneumonia,
tryptase 273–276
- C**₁₈ fatty acid
lymphocyte, reactive oxygen
species 245–253
- Cardiac autonomic neuropathy
autonomic nervous system, Type II
diabetes 93–99
- Cardiac health
heart failure, natriuretic peptide
23–36
- Cardiac remodelling
hypertension, statin 349–355
- Cardiovascular disease
cytokine, inflammation 205–213
- Cardiovascular reactivity
familial Mediterranean fever, fractal
analysis 37–46
- Cardiovascular risk factor
complement, coronary heart
disease 129–135
- Catecholamine
adipose tissue, weight loss
323–329
- β -Cell
amino acid metabolism, diabetes
185–194
- Cell-replacement therapy
neurological disorder, stem cell
13–22
- Cell therapy
regeneration, transdifferentiation
309–321
- Cholesterol metabolism
atherosclerosis, polymorphism
539–546
- Chronic eosinophilic pneumonia
bronchoalveolar lavage, tryptase
273–276
- Complement
cardiovascular risk factor, coronary
heart disease 129–135
ischaemia/reperfusion, skeletal
muscle 47–53
- Congenital central hypoventilation
syndrome
blood pressure, heart rate
variability 215–216, 225–230
- Coronary artery disease
cardiovascular risk factor,
complement 129–135
- C-reactive protein (CRP)
atherosclerosis, osteoprotegerin
237–243
endothelial cell, Fc γ receptor
85–91
endothelial dysfunction, Type II
diabetes 121–128
inflammation, statin 493–495,
515–521

- Cytokine
cardiovascular disease,
inflammation 205–213
- D**Diabetes
amino acid metabolism, β -cell
185–194
ascorbic acid (vitamin C), oxidative
stress 507–513
oxidative stress, end-stage renal
disease 497–506
- Diet
 β -adrenergic receptor, catecholamine
- Dipeptidyl peptidase IV (DPIV)
adenosine deaminase, post-proline
aminopeptidase 277–292
- Disease model
mutagenesis, neurological disorder
385–397
- Diurnal variation
non-invasive measurement, vascular
function 425–431
- E**chocardiography
marathon, oxidative stress 73–80
- Eicosanoid
fibrotic lung disease, leukotriene
479–491
- Endothelial cell
C-reactive protein (CRP), Fc γ
receptor 85–91
- Endothelial dysfunction
bosentan, ischaemia/reperfusion
357–363
C-reactive protein (CRP), Type II
diabetes 121–128
myocardial infarction, vitamin
supplementation 65–72
- Endothelial function
angiotensin-converting enzyme
(ACE), heart failure 331–338
high-cholesterol diet, plaque
formation 531–538
myometrial vessel, pre-eclampsia
457–462
- Endothelin
factor VIIa, protease-activated
receptor (PAR) 255–263
- Endothelin receptor antagonist
airway obstruction, smoke
inhalation and burn injury
265–272
- End-stage renal disease
diabetes, oxidative stress 497–506
- Epithelial cell differentiation
prostate cancer, stem cell 1–11
- Eprosartan
haemodynamics, hypoglycaemia
113–119
- Essential hypertension
 α -adducin polymorphism,
sodium–lithium countertransport
231–236
- Expression profiling
proteomics, tumour 369–383
- F**actor VIIa
endothelin, protease-activated
receptor (PAR) 255–263
- Familial Mediterranean fever
cardiovascular reactivity, fractal
analysis 37–46
- Fc γ receptor
C-reactive protein (CRP),
endothelial cell 85–91
- Fibrotic lung disease
eicosanoid, leukotriene 479–491
- Folic acid
homocysteine, remethylation
449–456
- Forkhead
pancreatic development, winged-
helix transcription factor
195–204
- Fractal analysis
cardiovascular reactivity, familial
Mediterranean fever 37–46
- Frizzled
angiotensin, vascular smooth
muscle 523–530
- H**aemodynamics
eprosartan, hypoglycaemia 113–119
- Heart failure
angiotensin-converting enzyme
(ACE), endothelial function
331–338
natriuretic peptide, cardiac health
23–36
- Heart rate variability
blood pressure, congenital central
hypoventilation syndrome
215–216, 225–230
- High-cholesterol diet
endothelial function, plaque
formation 531–538
- Homocysteine
folic acid, remethylation 449–456
- 5-Hydroxytryptamine (5-HT)
blood pressure, hypertension
399–412
- Hypertension
baroreceptor sensitivity, organ
damage 547–552
blood pressure,
5-hydroxytryptamine (5-HT)
399–412
cardiac remodelling, statin 349–355
lipoprotein lipase, triacylglycerol
metabolism 137–142
- Hypoglycaemia
eprosartan, haemodynamics
113–119
- I**nflammation
cardiovascular disease, cytokine
205–213
C-reactive protein (CRP), statin
493–495, 515–521
- Insulin resistance
metabolic syndrome, risk factor
553–559
pregnancy, resistin 81–84
- Intracerebral artery
non-invasive measurement,
transcranial Doppler 433–439
- Ion channel
long QT syndrome, missense
mutation 143–150
- Ischaemia/reperfusion
bosentan, endothelial dysfunction
357–363
complement, skeletal muscle 47–53
- Ischaemic preconditioning
liver, steatosis 55–63
- Ischaemic stroke
aortic stiffness, baroreceptor
sensitivity 441–447
- L**eukotriene
eicosanoid, fibrotic lung disease
479–491
- Lipoprotein lipase
hypertension, triacylglycerol
metabolism 137–142
- Liver
ischaemic preconditioning, steatosis
55–63
- Long QT syndrome
ion channel, missense mutation
143–150
- Lower limb ischaemia
muscle oxygenation, spectroscopy
159–165
- Lymphocyte
C₁₈ fatty acid, reactive oxygen
species 245–253

- Marathon**
 echocardiography, oxidative stress 73–80
- Metabolic rate**
 protein synthesis, tonsil 179–184
- Metabolic syndrome**
 insulin resistance, risk factor 553–559
- Migraine**
 persistent foramen ovale, right-to-left shunt 365–367
- Missense mutation**
 ion channel, long QT syndrome 143–150
- Muscle oxygenation**
 lower limb ischaemia, spectroscopy 159–165
- Mutagenesis**
 disease model, neurological disorder 385–397
- Myocardial infarction**
 endothelial dysfunction, vitamin supplementation 65–72
 peripheral blood mononuclear cell, tumour necrosis factor (TNF) 339–347
- Myometrial vessel**
 endothelial function, pre-eclampsia 457–462
- Natriuretic peptide**
 cardiac health, heart failure 23–36
- Neurological disorder**
 cell-replacement therapy, stem cell 13–22
 disease model, mutagenesis 385–397
- Neutrophil**
 antineutrophil cytoplasm antibody (ANCA), small vessel vasculitis 101–112
 apoptosis, systemic inflammatory response syndrome (SIRS) 413–424
- Non-invasive measurement**
 diurnal variation, vascular function 425–431
 intracerebral artery, transcranial Doppler 433–439
- Organ damage**
 baroreceptor sensitivity, hypertension 547–552
- Osteoprotegerin**
 atherosclerosis, C-reactive protein (CRP) 237–243
- Oxidative stress**
 ascorbic acid (vitamin C), diabetes 507–513
 echocardiography, marathon 73–80
 diabetes, end-stage renal disease 497–506
- Pancreatic development**
 forkhead, winged-helix transcription factor 195–204
- Peripheral blood mononuclear cell**
 myocardial infarction, tumour necrosis factor (TNF) 339–347
- Persistent oramen ovale**
 migraine, right-to-left shunt 365–367
- Placenta**
 pre-eclampsia, resistin 81–84
- Plaque formation**
 endothelial function, high-cholesterol diet 531–538
- Polymorphism**
 atherosclerosis, cholesterol metabolism 539–546
- Post-proline aminopeptidase**
 adenosine deaminase, dipeptidyl peptidase IV (DPIV) 277–292
- Pre-eclampsia**
 endothelial function, myometrial vessel 457–462
 placenta, resistin 81–84
- Prostate cancer**
 androgen receptor, Ras signalling 293–308
 epithelial cell differentiation, stem cell 1–11
- Protease-activated receptor (PAR)**
 endothelin, factor VIIa 255–263
- Protein clearance**
 autologous plasma, volume expansion 217–224
- Protein synthesis**
 metabolic rate, tonsil 179–184
- Proteomics**
 expression profiling, tumour 369–383
 surgical stress, transcriptomics 167–178
- Ras signalling**
 androgen receptor, prostate cancer 293–308
- Reactive oxygen species**
 C₁₈ fatty acid, lymphocyte 245–253
- Regeneration**
 cell therapy, transdifferentiation 309–321
- Remethylation**
 folic acid, homocysteine 449–456
- Resistin**
 pre-eclampsia, placenta 81–84
- Right-to-left shunt**
 migraine, persistent foramen ovale 365–367
- Risk factor**
 insulin resistance, metabolic syndrome 553–559
- Skeletal muscle**
 complement, ischaemia/reperfusion 47–53
- Small vessel vasculitis**
 antineutrophil cytoplasm antibody (ANCA), neutrophil 101–112
- Smoke inhalation and burn injury**
 airway obstruction, endothelin receptor antagonist 265–272
- Smooth muscle**
 airway remodelling, asthma 463–477
- Sodium–lithium countertransport**
 α -adducin polymorphism, essential hypertension 231–236
- Spectroscopy**
 lower limb ischaemia, muscle oxygenation 159–165
- Statin**
 cardiac remodelling, hypertension 349–355
 C-reactive protein (CRP), inflammation 493–495, 515–521
- Steatosis**
 ischaemic preconditioning, liver 55–63
- Stem cell**
 cell-replacement therapy, neurological disorder 13–22
 epithelial cell differentiation, prostate cancer 1–11
- Surgical stress**
 proteomics, transcriptomics 167–178
- Systemic inflammatory response syndrome (SIRS)**
 apoptosis, neutrophil 413–424
- Tonsil**
 metabolic rate, protein synthesis 179–184
- Transcranial Doppler**
 intracerebral artery, non-invasive measurement 433–439

- Transcriptomics
 proteomics, surgical stress 167–178
- Transdifferentiation
 cell therapy, regeneration 309–321
- Triacylglycerol metabolism
 hypertension, lipoprotein lipase
 137–142
- Tryptase
 bronchoalveolar lavage, chronic
 eosinophilic pneumonia 273–276
- Tumour
 expression profiling, proteomics
 369–383
- Tumour necrosis factor (TNF)
 myocardial infarction, peripheral
 blood mononuclear cell 339–347
- Type II diabetes
 autonomic nervous system,
 cardiac autonomic neuropathy
 93–99
- C-reactive protein (CRP),
 endothelial dysfunction 121–128
- V**ascular function
 diurnal variation, non-invasive
 measurement 425–431
- Vascular resistance
 blood flow, venous occlusion
 plethysmography 151–157
- Vascular smooth muscle
 angiotensin, frizzled 523–530
- Venous occlusion plethysmography
 blood flow, vascular resistance
 151–157
- Vitamin supplementation
 endothelial dysfunction, myocardial
 infarction 65–72
- Volume expansion
 autologous plasma, protein
 clearance 217–224
- W**eight loss
 adipose tissue, catecholamine
 323–329
- Winged-helix transcription factor
 forkhead, pancreatic development
 195–204